The protein kinase C-β inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.12, 2005-12, pp. : 1547-1559

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Protein kinase C βII in diabetic complications: survey of structural, biological and computational studies

By Sobhia M Elizabeth Grewal Baljinder K Bhat Jyotsna Rohit Shishir Punia Vijay

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 3, 2012-03 ,pp. : 325-344

Informa Healthcare

Access to resources Recommend Favorite

Ruboxistaurin: PKC-β inhibition for complications of diabetes

By Danis Ronald P Sheetz Matthew J

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 17, 2009-12 ,pp. : 2913-2925

Informa Healthcare

Access to resources Recommend Favorite

Protein Kinase C Inhibitors in the Treatment of Diabetic Retinopathy. Review

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 3, 2011-01 ,pp. : 386-391

Bentham Science Publishers

Access to resources Recommend Favorite

Lipoproteins and Diabetic Microvascular Complications

Current Pharmaceutical Design, Vol. 10, Iss. 27, 2004-10 ,pp. : 3395-3418

Bentham Science Publishers

Access to resources Recommend Favorite

Aldose Reductase in Diabetic Microvascular Complications

Current Drug Targets, Vol. 6, Iss. 4, 2005-06 ,pp. : 475-486

Bentham Science Publishers

Access to resources Recommend Favorite